Diabetes and osteoporosis;Diabète et ostéoporose

Revue Medicale Suisse

Volumn 9, Issue 390, 2013, Pages 1256-1259

  Ferrari, Serge ^a  

^a HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; INSULIN; ORAL ANTIDIABETIC AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE DENSITY; BONE MASS; DIABETES MELLITUS; DRUG EFFICACY; FAT MASS; FRACTURE; GLYCEMIC CONTROL; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; WEIGHT GAIN;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84880293712     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol 2012;771:42-50.
2. * Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005;48:1292-9. (Pubitemid 41186093)
3. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404-10. (Pubitemid 44402111)
4. * Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms. World J Diabetes 2011;2:41-8.
5. Hamrick MW, Ferrari SL. Leptin and the sympathetic connection of fat to bone. Osteoporos Int 2008;19:905-12. (Pubitemid 351758616)
6. Napoli N, Pedone C, Pozzilli P, et al. Adiponectin and bone mass density: The InCHIANTI study. Bone 2010;47:1001-5.
7. Maggio AB, Ferrari S, Kraenzlin M, et al. Decreased bone turnover in children and adolescents with well controlled type 1 diabetes. J Pediatr Endocrinol Metab 2010;23:697-707.
8. Adami S. Bone health in diabetes: Considerations for clinical management. Curr Med Res Opin 2009;25:1057-72.
9. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008;93:1013-9. (Pubitemid 351398587)
10. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007;22:1317-28. (Pubitemid 351339677)
11. Hamilton EJ, Rakic V, Davis WA, et al. A five-year prospective study of bone mineral density in men and women with diabetes: The Fremantle Diabetes Study. Acta Diabetol 2012;49:153-8.
12. * Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011;305:2184-92.
13. Leslie WD, Aubry-Rozier B, Lamy O, Hans D. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab 2013;98:602-9.
14. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: An analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 2008;31:845-51.
15. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5. (Pubitemid 351620084)
16. Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: The fracture intervention trial. Diabetes Care 2004;27:1547-53. (Pubitemid 38857424)
17. Vestergaard P, Rejnmark L, Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes ? Calcif Tissue Int 2011;88:209-14.